Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia

Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Nov 29, 2022

Keywords

ClinConnect Summary

This clinical trial is looking to understand how well patients with Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler Disease, tolerate treatment with blood-thinning medications. Researchers want to compare how patients feel and respond during the first few months of treatment with these medications to their experiences in the months right before they started the treatment. This information can help doctors make better decisions about using these medications in the future.

To be eligible for the study, participants must be adults aged 18 or older who have recently started taking antiplatelet or anticoagulant medications for their condition. They should also be able to understand the study and agree to participate. Those with other specific circumstances, like being pregnant or having certain legal restrictions, will not be able to join. If you choose to participate, you can expect to share your experiences with the treatment, which will help improve care for others with HHT.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with Rendu-Osler disease with an indication of antiplatelet and/or anticoagulant introduced for less than 3 months (inclusion period within 3 months of exposure)
• • Age \> 18 years old
• • Patient able to understand and agree to participate in the study
• • Affiliation to a social security system
• Exclusion Criteria:
• • Patient with an indication of antiplatelet and/or anticoagulant but for whom treatment has not been introduced or introduced for more than 3 months
• • Refusal to participate
• • Pregnant woman or who are breast feeding
• • Patients under maintenance of justice, wardship or legal guardianship